Patient dosing is expected to be completed in the December quarter of 2021 with results due in first quarter
of 2022. These results will be used to support an investigational new drug (IND) application with the FDA and
to inform the design of subsequent clinical trials. In July 2021, confidential interim analysis of the data from
the clinical trial was performed and these results were used to support a patent application regarding the
methods for the treatment of OSA.
Incannex has also commenced an open label extension to the phase 2 clinical trial. The open label extension
study has recruited people who have experienced a benefit from IHL-42X in the phase 2 trial and will assess
the therapeutic benefit and tolerability of IHL-42X in those patients over an extended timeframe of 6 months.
Just confirms positive results once again and why engage further capsule production if results were tepid!
risk reducing every day.
- Forums
- ASX - By Stock
- IHL
- Ann: Incannex engages Procaps to produce IHL-42X
Ann: Incannex engages Procaps to produce IHL-42X, page-5
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online